CA2084208A1 - Inhibiteurs de croissance et methode de traitement de cancer et des maladies a proliferation cellulaire - Google Patents

Inhibiteurs de croissance et methode de traitement de cancer et des maladies a proliferation cellulaire

Info

Publication number
CA2084208A1
CA2084208A1 CA002084208A CA2084208A CA2084208A1 CA 2084208 A1 CA2084208 A1 CA 2084208A1 CA 002084208 A CA002084208 A CA 002084208A CA 2084208 A CA2084208 A CA 2084208A CA 2084208 A1 CA2084208 A1 CA 2084208A1
Authority
CA
Canada
Prior art keywords
group
och3
acyloxy
alkyl
halogens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002084208A
Other languages
English (en)
Inventor
Barry Markaverich
Rebecca Gregory
Rejender Singh Varma
Manju Varma
James Clark
John Clifford Waldrep
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2084208A1 publication Critical patent/CA2084208A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002084208A 1990-05-17 1991-05-06 Inhibiteurs de croissance et methode de traitement de cancer et des maladies a proliferation cellulaire Abandoned CA2084208A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52527090A 1990-05-17 1990-05-17
US525,270 1990-05-17

Publications (1)

Publication Number Publication Date
CA2084208A1 true CA2084208A1 (fr) 1991-11-18

Family

ID=24092578

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002084208A Abandoned CA2084208A1 (fr) 1990-05-17 1991-05-06 Inhibiteurs de croissance et methode de traitement de cancer et des maladies a proliferation cellulaire

Country Status (5)

Country Link
EP (1) EP0528975A4 (fr)
JP (1) JPH05509078A (fr)
AU (1) AU7963691A (fr)
CA (1) CA2084208A1 (fr)
WO (1) WO1991017749A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5686465A (en) * 1988-10-31 1997-11-11 Endorecherche Inc. Sex steroid activity inhibitors
US5393785A (en) * 1988-10-31 1995-02-28 Endorecherche, Inc. Therapeutic antiestrogens
US6060503A (en) * 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
GB9126209D0 (en) * 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
IT1271301B (it) * 1994-12-20 1997-05-27 Indena Spa Calconi naturali e sintetici e loro esteri ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno e formulazioni che li contengono
GB9712966D0 (en) * 1997-06-19 1997-08-27 Indena Spa Novel chalcones
US6423740B1 (en) 1997-06-19 2002-07-23 Indena S.P.A. Chalcones having antiproliferative activity
GB9920908D0 (en) 1999-09-03 1999-11-10 Indena Spa Chalcone coumarins
GB9920910D0 (en) * 1999-09-03 1999-11-10 Indena Spa Novel chalcones
EP1623704A4 (fr) * 2003-05-02 2009-04-01 Takara Bio Inc Agent therapeutique
WO2005063774A1 (fr) * 2003-12-22 2005-07-14 Johns Hopkins University Analogues d'aryle d'acide boronique
JP2006290886A (ja) * 2005-04-06 2006-10-26 Engelhard Lyon Sa 少なくとも１種のアウロンを適用することによる美容的脱色素沈着ケア方法
EP1899360A1 (fr) * 2005-06-24 2008-03-19 DSMIP Assets B.V. Composés pour le traitement du syndrome x et/ou de diabetes mellitus de type 2 non auto-immun
CN101011377A (zh) * 2006-09-07 2007-08-08 复旦大学 化合物s6在制备抗癌药物中的应用
TW201036608A (en) * 2009-03-27 2010-10-16 Biotropics Malaysia Berhad Aurones as estrogen receptor modulators and their use in sex hormone dependent diseases
TW201036624A (en) * 2009-03-27 2010-10-16 Biotropics Malaysia Berhad Aurones as selective PDE inhibitors and their use in neurological conditions and disorders
CN107253915A (zh) 2010-08-20 2017-10-17 有联生技股份有限公司 1，5‑二苯基‑戊‑1，4‑二烯‑3‑酮化合物
WO2014022660A1 (fr) * 2012-08-03 2014-02-06 Georgia State University Research Foundation, Inc. Analogues de curcumine et procédés de fabrication et d'utilisation de ceux-ci
FR3007970B1 (fr) * 2013-07-02 2016-08-12 Oreal Utilisation de derives de l'acide 4-hydroxyphenoxy-acetique en tant qu'agents apaisants
CN103467320B (zh) * 2013-08-15 2015-12-23 沈阳药科大学 2,5-双取代环戊酮类衍生物及其应用
WO2017103637A1 (fr) 2015-12-18 2017-06-22 Blirt S.A. Composés de diphénylpropane et leur activité cytotoxique
EP3442520A4 (fr) 2016-04-11 2020-04-22 Middle Tennessee State University Aurones thérapeutiques
JP7106648B2 (ja) * 2017-12-27 2022-07-26 アンスティテュ パスツール デ モンテビデオ ニトロアルケン非ステロイド性抗炎症薬（ｎａ－ｎｓａｉｄ）および炎症関連症状を治療する方法
CN114304062B (zh) * 2020-09-30 2022-12-06 北京市眼科研究所 一种自身免疫性视网膜病变动物模型的构建方法及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1568633A1 (de) * 1966-12-02 1970-03-19 Bayer Ag Verfahren zur Herstellung von Cyclopentanonderivaten
JPS6242925A (ja) * 1985-08-20 1987-02-24 Kanegafuchi Chem Ind Co Ltd 酵素阻害剤
US4898890A (en) * 1986-06-21 1990-02-06 Dainippon Ink And Chemicals, Inc. Medicines for use in the therapy and prevention of kidney and liver diseases

Also Published As

Publication number Publication date
EP0528975A4 (en) 1993-09-15
WO1991017749A1 (fr) 1991-11-28
EP0528975A1 (fr) 1993-03-03
AU7963691A (en) 1991-12-10
JPH05509078A (ja) 1993-12-16

Similar Documents

Publication Publication Date Title
CA2084208A1 (fr) Inhibiteurs de croissance et methode de traitement de cancer et des maladies a proliferation cellulaire
CA1332742C (fr) Inhibiteurs de la croissance cellulaire et methodes de traitement du cancer et des maladies cellulaires proliferatives
Niles et al. Resveratrol is rapidly metabolized in athymic (nu/nu) mice and does not inhibit human melanoma xenograft tumor growth
JP2001518935A (ja) 抗癌剤としてのジ―アリールエーテル類及びそれらの誘導体
CZ20011979A3 (cs) Preparát pro léčbu rakoviny a způsob pouľití přirozených rostlinných olejů
Leav et al. Bipotentiality of response to sex hormones by the prostate of castrated or hypophysectomized dogs. Direct effects of estrogen.
WO1992004310A1 (fr) Acides carboxyliques de triarylethylene a activite estrogene
HUT73177A (en) Fatty acid derivatives and pharmaceutical compositions containing them
JP2012510965A (ja) 結腸癌発生を予防または低減する方法
BE1011382A5 (fr) Methodes de prevention du cancer du sein.
Stanberry et al. Photoperiodic control of melanoma growth in hamsters: influence of pinealectomy and melatonin
HU224346B1 (hu) Cisz-N-ciklohexil-N-etil-[3-(3-klór-4-ciklohexilfenil)allil]amin alkalmazása tumorsejtek szaporodását gátló hatású gyógyászati készítmények előállítására
Welsch Prolactin and the development and progression of early neoplastic mammary gland lesions
US6855732B2 (en) Compounds to treat diabetes and associated conditions
WO1987000432A2 (fr) Compositions contenant de la melatonine ou ses homologues, leurs utilisations pour le traitement du psoriasis vulgaris et/ou des affections apparentees
US5264428A (en) Use of stigmasta-4-en-3-one in the treatment of androgen dependent diseases
WO1993001824A1 (fr) Therapie combinee utilisant des composes bioflavonoides avec des medicaments anticancer
JP2002503713A (ja) Ｅ−２−［４−（４−クロロ−１，２−ジフェニル−ブテ−１−エニル）フェノキシ］エタノールおよびその医薬組成物
CA2257898C (fr) Utilisation de derives aminothiolesters dans le domaine pharmaceutique
Anisimov Carcinogenesis and aging: III. The role of age in initiation and promotion of carcinogenesis
Attramadal Cellular localization of 3H-oestradiol in the hypophysis: An autoradiographic study in male and female rats
Longnecker et al. Regulation of growth and differentiation in pancreatic cancer
US6281250B1 (en) Retinyl ethers, derivatives and analogues and inhibition of breast carcinogenesis
Welsch et al. 6-methyl-8-β-ergoline-acetonitrile (MEA)-induced suppression of mammary tumorigenesis in C3H/HeJ female mice
Briand et al. Effect of prolactin and bromocriptine on growth of transplanted hormone-dependent mouse mammary tumours

Legal Events

Date Code Title Description
FZDE Dead